 NOTE: Patients with evidence of tumor shrinkage may receive up to 3 courses of high-dose aldesleukin therapy. Patients with stable disease by Response Evaluation Criteria in Solid Tumors RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two courses will receive only entinostat until disease progression is documented. 